Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico
2023 ASCO Annual Meeting
Paula Aristizabal, MD, MAS, of the University of California, San Diego, and Rady Children’s Hospital, talks about using a health systems strengthening approach to improve leukemia care and survival in a public Mexican hospital in the region of the border between the United States and Mexico. The demonstrated increase in overall survival across a decade after implementation of the program seems to validate the use of such models, not only to improve clinical outcomes, but also to build sustainable hospital capacity, financially and organizationally (Abstract 1502).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Paula Aristizabal, MD:
Acute lymphoblastic leukemia is the most common childhood cancer and survival has improved dramatically in high income countries to rates over 80%. Unfortunately, in low and middle income countries, survival has not increased at the same pace. For example, in Mexico, a low income country that is just across the border from the US, survival range is between 10% and 60%. Since in San Diego we share a border with Tijuana, we saw the disparities and we thought that it was our social responsibility to do something about it so we implemented a twinning program and twinning involves when a center of excellence in a high income country partners and collaborates with a center in a low, middle income country. We started this twinning program in 2008 in collaboration with St. Jude Children's Research Hospital, and we were able to implement a new team in Tijuana that was able to provide the best care possible for all the pediatric cancers.
Then in 2013, we realized that the burden of leukemia was getting higher and higher and we decided to implement a new model of health system strengthening called the WHO Framework for Action. The WHO Framework for Action has six building blocks that provide all the elements to improve care in a health system. We incorporated the WHO Framework for Action into the already existing twinning model to improve leukemia survival. We provided training to the team in Tijuana. We provided protocols that they could adapt. We provided mentorship and we provided support for a new infrastructure to develop the best possible leukemia care for children with with leukemia in Baja, California, Mexico.
After the implementation of the program, survival for leukemia improved from 59% to 65% and, importantly, the survival for standard risk leukemia improved from 73% before implementing the program to 100%, which is totally amazing because that is the same survival that we have in San Diego, just 20 miles from Tijuana. Survival for high risk leukemia improved from 48% to 55%. It wasn't so significant but we know that that is an area of improvement that we hope that we can tackle in our next steps of the program. Our model in Tijuana, combining a twinning program with the WHO Framework for Action, was effective in improving survival in a low and middle income country. This model can be applicable to a partnership between a high income country and a low, middle income country, especially in regions that share a border but also in other low and middle income countries remotely. Something that we learned from COVID is that you can apply many of these models working remotely and we are extremely pleased with these results. Our next steps include the improvement of the survival for patients with high risk leukemia.
Related Videos
The ASCO Post Staff
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses phase II findings from the waveLINE-004 study. It showed that the antibody-drug conjugate zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who experienced disease progression after, or have been ineligible for, autologous stem cell transplantation and/or chimeric antigen receptor T-cell therapy (Abstract 7531).
The ASCO Post Staff
Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III findings from the PRODIGE 23 trial, showing that neoadjuvant chemotherapy with mFOLFIRINOX followed by chemoradiotherapy, surgery, and adjuvant chemotherapy improved all outcomes, including overall survival, in patients with locally advanced rectal cancer compared with standard chemoradiotherapy, surgery, and adjuvant chemotherapy (Abstract LBA3504).
The ASCO Post Staff
Amer Methqal Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, discusses phase III findings on the first-in-class telomerase inhibitor imetelstat, which was given to patients with heavily transfusion-dependent non-del(5q) lower-risk myelodysplastic syndromes that are resistant to erythropoiesis-stimulating agents. Imetelstat resulted in a significant and sustained red blood cell (RBC) transfusion independence in 40% of these heavily transfused patients. The response was also durable and accompanied by an impressive median hemoglobin rise of 3.6 g/dL, and seen in patients with and without ring sideroblasts. Importantly, reduced variant allele frequency was observed in the most commonly mutated myeloid genes which correlated with duration of transfusion independence and hemoglobin rise, therefore suggesting a disease-modifying potential of this agent (Abstract 7004).
The ASCO Post Staff
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).
The ASCO Post Staff
Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the COMMANDS trial. Compared with epoetin alfa, luspatercept improved red blood cell transfusion independence and erythroid response, as well as the duration of response in erythropoiesis-stimulating agent–naive, transfusion-dependent patients with lower‐risk myelodysplastic syndromes (Abstract 7003).